Pharmaceutica Analytica Acta

Transdermal Microneedle Patch for Peptide Delivery: Clinical Advances

2^nd International Conference on Pharmaceutics & Novel Drug Delivery Systems

20-22 February 2012 San Francisco Airport Marriott Waterfront, USA

Peter Daddona

Accepted Abstracts: Pharm Anal Acta

Abstract:

Microneedle technology is being developed for peptide and proteins as a patient- friendly alternative to subcutaneous and intravenous injection. While several microneedle formats are in early development Zosano has focused on drug-coated microneedle patch optimization. This talk will highlight our technology validation in clinical trials. Our studies demonstrate that delivery of parathyroid hormone peptide (PTH 1-34) is feasible for the treatment of severe osteoporosis and warrants further clinical development toward approval of the first commercial microneedle patch product

Biography :

Peter Daddona is founder and Chief Scientific Officer of Zosano Pharma, a spin out company from ALZA Corp/J&J. He is responsible for strategic planning and research/early development. Prior to that he was VP of Macroflux? Technology Development at ALZA/J&J and Consulting Associate Professor of Dermatology at Stanford University. Before joining ALZA, he served as Vice President, Immunobiology Research at Centocor/J&J.